Rigel Pharmaceuticals (RIGL) Is Up 20.5% After Global VEPPANU Rights Deal With Pfizer, Arvinas - Has The Bull Case Changed?

Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer, which was approved in May 2026 following positive Phase 3 VERITAC-2 data. A key nuance is that Rigel assumes worldwide commercialization rights, including the option to sublicense outside the U.S., while Arvinas and Pfizer retain upside through royalties, milestones of up to US$320.00 million, and a share of sublicensing revenue, aligning all parties to VEPPANU’s long-term adoption. We’ll now examine how taking over global commercialization of VEPPANU, with strong Phase 3 support, may reshape Rigel’s investment narrative.

Invest in the nuclear renaissance through our list of 87 elite nuclear energy infrastructure plays powering the global AI revolution.

Rigel Pharmaceuticals Investment Narrative Recap

To own Rigel today, you have to believe it can turn a concentrated hematology and oncology portfolio into a broader, durable franchise. The VEPPANU license meaningfully reframes that story by adding an FDA‑approved oncology product, but it also shifts the near term catalyst to successful U.S. launch and early uptake, while increasing execution risk around integrating and commercializing a complex, royalty‑bearing asset alongside existing products.

The reaffirmed 2026 revenue guidance of US$275 million to US$290 million, issued just days before the VEPPANU deal, gives investors a reference point that predates this transaction. How, or if, management updates that outlook once the license closes could become an important marker for VEPPANU’s impact on Rigel’s near term growth profile and its dependence on Tavalisse and the rest of the current portfolio.

Yet behind the promise of VEPPANU, investors should be aware of the heightened reliance on a small set of commercial assets and...

Read the full narrative on Rigel Pharmaceuticals (it's free!)

Rigel Pharmaceuticals' narrative projects $297.0 million revenue and $42.4 million earnings by 2028. This requires 3.5% yearly revenue growth and a $55.4 million earnings decrease from $97.8 million.

Uncover how Rigel Pharmaceuticals' forecasts yield a $51.60 fair value, a 61% upside to its current price.

Exploring Other PerspectivesRIGL 1-Year Stock Price Chart

Before this news, the most optimistic analysts were already modeling about US$443 million of revenue and US$123 million of earnings by 2029, a much more upbeat view than consensus that could shift further as VEPPANU and Rigel’s exposure to pricing and reimbursement pressures come into clearer focus.

Story Continues

Explore 6 other fair value estimates on Rigel Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your Rigel Pharmaceuticals research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Our free Rigel Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rigel Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

Outshine the giants: these 16 early-stage AI stocks could fund your retirement. AI is about to change healthcare. These 33 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. We've uncovered the 14 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include RIGL.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments